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Abstract: Articular cartilage repair might be stimulated by the controlled delivery of
therapeutic factors. We tested the hypotheses whether TGF-ß1 can be released from a polymeric
scaﬀold over a prolonged period of time in vitro and whether its transplantation modulates
cartilage repair in vivo. Unloaded control or TGF-ß1 poly(ether-ester) copolymeric scaﬀolds
were applied to osteochondral defects in the knee joints of rabbits. In vitro, a cumulative dose
of 9 ng TGF-ß1 was released over 4 weeks. In vivo, there were no adverse eﬀects on the synovial
membrane. Defects treated with TGF-ß1 scaﬀolds showed no signiﬁcant diﬀerence in individual
parameters of chondrogenesis and in the average cartilage repair score after 3 weeks. There was
a trend towards a smaller area (42.5 %) of the repair tissue that stained positive for safranin O
in defects receiving TGF-ß1 scaﬀolds. The data indicate that TGF-ß1 is released from emulsion-
coated scaﬀolds over a prolonged period of time in vitro and that application of these scaﬀolds
does not signiﬁcantly modulate cartilage repair after 3 weeks in vivo. Future studies need to
address the importance of TGF-ß1 dose and release rate to modulate chondrogenesis.
c© Central European Science Journals Warsaw and Springer-Verlag Berlin Heidelberg. All rights reserved.
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1 Introduction
Traumatic lesions of adult articular cartilage do not regenerate [1, 2]. Cartilage defects
that penetrate the underlying subchondral bone are repopulated with mesenchymal cells
from the bone marrow, which diﬀerentiate into chondrocytes, deposit a cartilaginous
matrix, and form a ﬁbrocartilaginous repair tissue [3]. This repair tissue has inferior
structural characteristics and degenerates over the course of several months [2]. A variety
of approaches is currently used to clinically treat articular cartilage defects, including
marrow-stimulating techniques, the transplantation of isolated and expanded autologous
chondrocytes in the absence or presence of supportive biodegradable matrices or the
transplantation of cylindrical osteochondral autografts to sites of articular cartilage dam-
age. However, even such highly sophisticated procedures do not predictably lead to the
formation of articular cartilage that is identical in its structure to the normal cartilage
and capable of withstanding mechanical stresses over time [4]. The regeneration of the
original hyaline articular cartilage, therefore, remains a great challenge for orthopaedic
researchers and clinicians.
The process of chondrogenesis within a healing articular cartilage lesion can be en-
hanced by regenerative signals provided to the site of articular cartilage repair [5]. Trans-
forming growth factor-beta (TGF-ß) plays an important role in the growth and diﬀeren-
tiation of articular cartilage and promotes chondrogenic diﬀerentiation of mesenchymal
cells [6]. However, TGF-ß1, the predominant isoform of TGF-ß in articular cartilage, has
a very short half-life [7]. Recently, an emulsion-coating method was successfully used to
associate TGF-ß1 to porous poly(ether-ester) scaﬀolds and release the bioactive protein
in a controlled fashion [8]. These biodegradable hydrogels are based on poly(ethylene
glycol)-terephtalate and poly(butylene terephtalate) i.e., PEGT/PBT, and poly(ethylene
glycol)-succinate and poly(butylene succinate) i.e., PEGS/PBS and have been success-
fully used to release diﬀerent proteins [9]. Although PEGT/PBT porous scaﬀolds have
been previously used in tissue engineering applications [10] it remains unknown if trans-
plantation of TGF-ß1 scaﬀolds to sites of articular cartilage damage would modulate the
chondrogenesis and cartilage repair in vivo. In the present study, we tested the hypothesis
that TGF-ß1 can be released from a biodegradable polymeric scaﬀold over a prolonged
period of time in vitro. We further investigated whether transplantation of these scaﬀolds
in osteochondral defects modulates articular cartilage repair in vivo. To determine the
eﬀects of TGF-ß1 at the onset of chondrogenesis [3], 3 weeks after transplantation was
chosen as the optimal time for evaluation.
∗ E-mail: hmad@hotmail.com
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2 Experimental procedures
2.1 Materials
PEGT/PBT and PEGS/PBS multiblock copolymers were obtained from OctoPlus, Lei-
den, The Netherlands, and were used as received. Vitamin B12, bovine serum albumin
(BSA), and recombinant human TGF-ß1 were obtained from R&D Systems (Minneapolis,
USA). Roswell Park Memorial Institute medium (RPMI 1640) was purchased from Cam-
brex (East Rutherford, USA). Chloroform, obtained from Fluka (Buchs, Switzerland),
was of analytical grade.
2.2 Preparation of TGF-ß1-loaded polymeric scaﬀolds
The TGF-ß1 protein was associated to the porous scaﬀolds by means of a water-in-
oil emulsion method previously described [11]. TGF-ß1 in a 4-mM HCL aqueous so-
lution containing 1 mg/ml BSA (according to the supplier’s protocol) was emulsiﬁed
with PEGS/PBS copolymer solution in chloroform, using an Ultra-Turrax (T25 Janke &
Kunkel, IKA-Labortechnik, Staufen, Germany) for 30 s at 19 krpm. The TGF-ß1 con-
centration of the aqueous solution was set at 19.8 μg/ml and the volume of the aqueous
phase was set to 0.5 ml. The copolymer solution was obtained by dissolving 0.5 g of
copolymer in 3 ml of chloroform. The copolymer compositions used had a PEGS content
of 70 weight % and a PEG molecular weight of 1,000 g/mol.
Compression molded/salt leached scaﬀolds were obtained by applying pressure (10,000
PSI during 10 min) and heat (240 ◦C) to a homogeneous mix of NaCl salt crystals and
copolymer powder in a mold. The volume fraction of salt in the mixture was adjusted
to 75 %. After cooling of the resultant dense block, the salt was extracted by successive
immersions in RX-water (water conductivity less than 25 μS). Subsequently, the porous
blocks were dried in ambient air for at least 24 h, and then placed in a vacuum oven (50
◦C) for a minimum of 12 h. The PEGT/PBT copolymer used to prepare the scaﬀold had
a PEGT content of 55 weight % and a PEG molecular weight of 300 g/mol. The salt
crystals were sieved between 400 and 600 μm. Coated scaﬀolds were prepared by forcing
the TGF-ß1-containing emulsion through a prefabricated cylindrical porous scaﬀold (1
cm in diameter and 1 cm in length) with the use of a vacuum (300 mBars). This vacuum
was applied for at least 5 min, in order to evaporate as much chloroform as possible
from the emulsion, thereby creating a polymeric coating on the scaﬀold. The resulting
TGF-ß1-coated scaﬀolds (termed TGF-ß1 scaﬀolds) were frozen in liquid nitrogen, and
freeze-dried at room temperature for 24 h. Blank scaﬀolds (termed control scaﬀolds) were
prepared by using a TGF-ß1-free 4-mM HCL solution (with 1 mg/ml BSA) and the same
conditions as TGF-ß-containing scaﬀolds. For in vivo implantation and in vitro release
determination, 4-mm cylinders were aseptically cored from the coated scaﬀolds prepared
as described above. Each cylinder was subsequently cut to a length of 4 mm.
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2.3 Scanning electron microscopy
A Philips XL 30 ESEM-FEG was used to evaluate the internal morphology of the scaﬀolds.
The internal porous structure was observed by cutting the scaﬀolds along the longitudinal
axis with a razor blade. All samples were gold sputter-coated using a Cressington 108
auto apparatus before analysis.
2.4 Characterization of scaﬀold porosity and interconnection
The average porosity (%) of the scaﬀolds was evaluated from their dry weight, dry volume,
and density of the PEGT/PBT copolymer (density = 1.2 g/ml) according to the following
equation:
p = 1− sample weight
sample volume× 1.2 (1)
Three scaﬀold pieces were used to determine the porosity of a speciﬁc emulsion-coated
scaﬀold. The scaﬀold pore interconnection was quantiﬁed using a method that applies
Darcy’s law, as described elsewhere [11]. Brieﬂy, water is forced through the porous
samples by applying a constant pressure and the ﬂow rate is measured, from which the
sample permeability (κ, 10−12 m2) can be calculated. This parameter reﬂects the sample
porosity and pore interconnection.
2.5 In vitro release of TGF-ß1 protein
TGF-ß1-loaded scaﬀolds (4×4-mm cylinders of approximately 19 mg) were incubated in
1 ml RPMI 1640 medium at 37 oC, in polypropylene tubes. All samples were kept under
constant agitation (25 rpm). The release medium was entirely refreshed at various time
points, immediately frozen in liquid nitrogen, and conserved at -20 ◦C until quantiﬁca-
tion. TGF-ß1 concentration was quantiﬁed using an enzyme-linked immunosorbent assay
(ELISA) with a detection limit of 76 pg/ml (Quantikine human TGF-ß1 immunoassay,
R&D Systems). The TGF-ß1 used for the standards and the preparation of the releasing
scaﬀolds originated from the same batch. Aliquots of diﬀerent volumes were frozen in
liquid nitrogen immediately after reconstituting the protein solution and stored at −20
◦C. They were thawed immediately prior to use for scaﬀold preparation or as standards.
To determine the quantity of emulsion eﬀectively coated on the porous scaﬀold and
establish the amount of protein present, coated scaﬀolds were prepared in the same con-
ditions using a polymer emulsion containing 10 mg of vitamin B12 per g of polymer. The
size of this molecule allows a complete release within 3 days when entrapped in the copoly-
mers used in this study. The quantity of vitamin released is correlated to the amount
of polymer coated onto a given scaﬀold, as the vitamin is homogeneously distributed in
the emulsion. In turn, the amount of polymer coated can be related to the amount of
protein associated with the scaﬀold. The amount of vitamin released was calculated using
a standard curve of vitamin B12 in phosphate buﬀered saline and a spectrophotometer
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(El 312e, BioTek Instruments) at 380 nm. This indirect detection method was proven to
be accurate for lysozyme [11].
The amount of emulsion eﬀectively coated onto the scaﬀolds was 47 % of the emulsion
applied, while the weight of the coated scaﬀolds was close to 1 g. Therefore, the amount
of TGF-ß1 incorporated in a scaﬀold piece of 19 mg was about 85 ng.
To determine the stability of TGF-ß1 in the release medium, the absolute concen-
tration decrease of the growth factor was measured by ELISA. Fresh TGF-ß was added
to the release medium (1 ml) containing control scaﬀolds at a concentration of 3 and 7
ng/ml. After 1 day, the medium was collected in triplicate and assayed for concentration.
2.6 Transplantation of PEGT/PBT porous scaﬀolds to osteochondral
cartilage defects in vivo
The transplantation of PEGT/PBT porous scaﬀolds to articular cartilage defects in vivo
was performed in a previously described animal model [? ]. Animal procedures were
approved by the Saarland Governmental Animal Care Committee. Chinchilla bastard
rabbits (Charles River, Sulzfeld, Germany) were kept in air-conditioned rooms at con-
stant temperature and a regular light:dark cycle. They were fed a standard diet and
received water ad libitum. Six female rabbits (mean weight: 3.1±0.2 kg; six animals
per group) were anesthetized by intramuscular injection of Rompun (0.2 ml/kg of body
weight; Bayer, Leverkusen, Germany) and Ketavet (0.75 mg/kg of body weight; Phar-
macia & Upjohn, Erlangen, Germany). The knee joint was entered through a medial
parapatellar approach; the patella was dislocated laterally and the knee ﬂexed to 90◦.
Using a manual cannulated burr (3.5 mm in diameter; Synthes, Umkirch, Germany), a
cylindrical osteochondral defect was created in the patellar groove of each knee (n = 12 de-
fects). All defects were washed with PBS to remove debris and blotted dry. PEGT/PBT
porous scaﬀolds were press-ﬁt into the defects. The right and left knees alternately re-
ceived control or TGF-ß1 scaﬀolds. After reducing the patella, the knee was put through
a range of motion to assure the stability of the scaﬀolds. Incisions were closed in lay-
ers. Immediately postoperatively, animals were allowed full weight bearing without any
immobilization.
2.7 Histological and immunohistochemical analysis
Three weeks after implantation, rabbits were euthanized with Pentobarbital (150 mg/kg
body weight; Merial, Hallbergmoos, Germany) and the knee joints were rinsed with
1 ml PBS, exposed and examined for synovitis, osteophytes, or other reactions. The
appearance of the defect (color, integrity, contour) and the articulating surfaces were
documented. Distal femurs were retrieved, ﬁxed in 4 % phosphate-buﬀered formalin,
trimmed, and decalciﬁed. Paraﬃn-embedded frontal sections (5 μm) were stained with
safranin O, fast green, hematoxylin, and eosin according to routine histological protocols
[15].
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The synovial membrane was evaluated using a previously published scoring system
[16, 17]. The categories of the score included villus thickening (ﬁbrosis), villus architec-
ture (blunting), and the presence of inﬂammatory cell inﬁltrates. For type-II collagen
and type-I collagen immunostaining, deparaﬃnized sections were submerged for 30 min
in 0.3 % hydrogen peroxide. After washing with PBS and incubation in 0.1 % trypsin for
30 min, sections were washed with PBS and blocked with 3 % bovine serum albumin in
PBS (blocking buﬀer) for 30 min. Sections were then incubated with a 1:50 dilution of a
monoclonal mouse anti-type-II or type-I collagen IgG (Acris Antibodies, Hiddenhausen,
Germany) in blocking buﬀer for 24 h at 4◦C, washed, and exposed to a 1:500 dilution of
a biotinylated anti-mouse antibody (Vector Laboratories, Gru¨nberg, Germany) for 1 h
at room temperature. After washing with PBS, the sections were incubated for 30 min
with the avidin-biotin-peroxidase reagent (Vectastain Elite ABC kit; Vector Laborato-
ries), washed, and exposed to diaminobenzidine (Vector Laboratories). To control for
secondary immunoglobulins, sections were processed as above, excepting the secondary
antibody. Immunoreactivity to type-II collagen in the repair tissue was compared to that
of the adjacent normal articular cartilage, which served as a positive internal control.
Immunoreactivity to type-I collagen in the repair tissue was compared to that of the
subchondral bone adjacent to the normal articular cartilage, which served as a positive
internal control. A score was given to each knee: – no immunoreactivity; + weaker
immunoreactivity; ++ similar immunoreactivity; and +++ stronger immunoreactivity.
For the quantitative assessment of the repair tissue, serial histological sections of the
distal femora were taken at 200-μm intervals. Safranin O-stained sections within approx-
imately 1.0 mm from the center of the defect (n = 9-10 per defect) were analyzed using
the articular cartilage repair scoring system described by Sellers and colleagues [18, 19].
Speciﬁc parameters that were evaluated include ﬁlling of the defect, integration of the
new cartilage, safranin O staining, cell morphology, architecture within the defect and of
its surface, restoration of the subchondral bone, and tidemark. Scores were combined and
resulted in an average total score. Values ranged from 31 (empty defect without repair
tissue) to 0 points (normal articular cartilage, complete regeneration). A total of 110 sec-
tions were independently scored by two individuals without knowledge of the treatment
groups. The safranin O-positive area in the new tissue ﬁlling the defects was measured
on serial histological sections of the distal femora that were taken within approximately
0.6 mm from the center of the defects at 200-μm intervals (n = 3-6 per defect). Low
magniﬁcation images of the cartilage defects were acquired by a solid-state CCD cam-
era mounted on a BX-45 microscope (Olympus, Hamburg, Germany). The image on
the monitor was digitalized and the safranin O-positive area was manually outlined by
a blinded observer. The safranin O-positive area was calculated using the analySIS pro-
gram (Soft Imaging System, Mu¨nster, Germany). Collagen ﬁbrils were evaluated using
polarized light microscopy (Olympus).
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2.8 Statistical analysis
In vitro data were evaluated using ANOVA and expressed as mean±SD. In vivo, points
for each category and total score were compared between the two groups using a mixed
general linear model with repeated measures (knees nested within the same animals). All
continuous variables were tested for normality using the Kolmogorov-Smirnov goodness-
of-ﬁt method and no signiﬁcant skewness or kurtosis was detected. Therefore, continuous
data are expressed as mean ±95 % conﬁdence interval. A two-tailed P<0.05 was con-
sidered statistically signiﬁcant. Statistical analysis of the data was performed using the
SPSS software package (version 12.0, SPSS Inc., Chicago, USA).
3 Results
3.1 Human TGF-β1 is eﬃciently released from poly(ether-ester) copoly-
meric scaﬀolds over at least 4 weeks in vitro
The ability of the scaﬀold to release TGF-ß1 over a prolonged period of time is a prereq-
uisite for the localized delivery of the protein to cartilage defects in vivo. Accordingly, we
prepared scaﬀolds coated with TGF-ß1 using an emulsion-coating method. The morphol-
ogy of these scaﬀolds prior to implantation, evaluated by Scanning Electron Microscopy
(SEM), is presented in Figure 1. The average porosity of the control and TGF-ß1 scaf-
folds was 65±4 %. Pores were of various sizes and shapes, ranging from 80 to 650 μm,
and were visually interconnected. The interpore connection of the scaﬀolds was reﬂected
by their high permeability to water (κ), which averaged 78± 14× 10−12 m2.
Fig. 1 Cross sections of a TGF-β1-loaded porous scaﬀold examined by scanning electron
microscopy.
The in vitro release of TGF-ß1 from the porous scaﬀolds is depicted in Figure 2. A fast
release was observed during the ﬁrst 8 days, followed by a slow and linear release over the
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following 3 weeks. The total cumulative amount of growth factor released, as measured
by ELISA, was on average 7.5 ng after 8 days and 9 ng after 28 days. Remarkably,
the amount of TGF-ß1 released over 28 days only reached 9 % of the amount eﬀectively
entrapped in the scaﬀold (85 ng).
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Fig. 2 Cumulated release of TGF-β1 from 4×4 mm cylindrical porous polymeric scaﬀolds.
At each time point, the release medium was collected and the amount of growth factor
released quantiﬁed by ELISA. (n = 3 ± S.D.).
3.2 Spatial delivery of human TGF-ß1 does not induce a synovial inﬂam-
matory response in vivo
Three weeks following implantation in osteochondral defects in each patellar groove of
rabbits, there were no macroscopic signs of inﬂammation or hematoma. The new tissue in
these defects had a white color and was still distinguishable from the neighboring normal
articular cartilage (Figure 3).
TGF-ß1 concentrations were monitored in the lavage ﬂuid of knees. After 3 weeks,
TGF-ß1 concentrations were below the detection limit of the assay in knees receiving
control or TGF-ß1 scaﬀolds (n = 6). We then investigated whether the released TGF-ß1
had an eﬀect on the synovial membrane. Analysis of the thickness, architecture of syn-
ovial villi, and presence of inﬂammatory cell inﬁltrates was performed using a previously
published score [17]. The data revealed no signiﬁcant diﬀerences between knees receiving
control or TGF-ß1 scaﬀolds at 3 weeks (P > 0.05, n = 6; Table 1).
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Fig. 3 Macroscopic view of femoral condyles receiving a control scaﬀold (left ; A) or a
TGF-ß1 scaﬀold (right ; B). Defects in both groups are ﬁlled with a new white tissue that
is distinguishable from the neighboring normal articular cartilage.
Category Control Scaﬀolds TGF-ß1 Scaﬀolds P value
Villus thickening 0.45 ± 0.42 0.44 ± 0.54 > 0.05
Villus architecture 0.29 ± 0.43 0.27 ± 0.42 > 0.05
Inﬂammatory cell inﬁltrate 0.12 ± 0.37 0.13 ± 0.41 > 0.05
Average total score 0.86 ± 0.17 0.84 ± 0.18 > 0.05
Eﬀects of TGF-ß1 scaﬀolds on the histological grading of the synovium at 3 weeks.
Table 1 Histological grading of the synovium at 3 weeks in vivo.
3.3 Poly(ether-ester) copolymeric scaﬀolds remain present in the osteo-
chondral defect for at least 3 weeks in vivo and allow cartilage for-
mation
After 3 weeks in vivo, the scaﬀolds remained in a subchondral location (Figure 4A, B).
Both control and TGF-ß1 scaﬀolds were ﬁlled with a tissue consisting of undiﬀerentiated
mesenchymal cells, histiocytic cells, and new bone, its trabeculae surrounding the bio-
material (Figure 5A-D). Polarized microscopy conﬁrmed the presence of trabecular bone
(data not shown). There were few signs of scaﬀold degradation.
3.4 Eﬀect of TGF-ß1 released from copolymeric scaﬀolds on chondroge-
nesis in vivo
The new tissue in the cartilage defects was analyzed by immunohistochemistry for the
presence of type-II collagen, a major component of the extracellular matrix of hyaline
articular cartilage (Figure 4E, F; Table 2). Three weeks after transplantation, immunore-
activity to type-II collagen was more pronounced in defects receiving TGF-β1 scaﬀolds
than in defects receiving control scaﬀolds.
Type-I collagen is mainly expressed in ﬁbrocartilage and in the subchondral bone.
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Fig. 4 Eﬀect of TGF-ß1 scaﬀolds on chondrogenesis in articular cartilage defects 3 weeks
after transplantation in vivo. Histological appearance of osteochondral defects following
implantation of a single control scaﬀold (left ; A, C, E, G) or a TGF-ß1 scaﬀold (right ; B,
D, F, H) stained with safranin O – fast green (A - D), a monoclonal mouse anti-human
type-II collagen IgG (E, F) or a monoclonal mouse anti-human type-I collagen IgG (G,
H).Images C and D are magniﬁed views of the left side of images A and B. Normal ar-
ticular cartilage can be identiﬁed on the far left side of Images (A – H) including the
area of integration between the repair tissue (right side of each picture) with the adjacent
normal articular cartilage (left side of each picture). The scaﬀolds remain in a subchon-
dral location and can be identiﬁed by their brown color (A, B). Photomicrographs were
obtained using standardized photographic parameters, including light intensity. Original
magniﬁcations ×10 (A, B), ×40 (C - H).
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Fig. 5 Eﬀect of TGF-ß1 scaﬀolds on new bone formation in the subchondral space 3
weeks after transplantation in vivo. Histological appearance of the subchondral bone
below the osteochondral defects that has been ﬁlled with a single control scaﬀold (left ; A,
C) or a TGF-ß1 scaﬀold (right ; B, D) stained with safranin O – fast green (A - D). New
subchondral bone has formed within the pores of the scaﬀold, its trabeculae surrounding
the biomaterial (C, D). Photomicrographs were obtained using standardized photographic
parameters, including light intensity. Original magniﬁcations ×40 (A, B), ×100 (C, D).
Animal number Control Scaﬀolds TGF-ß1 Scaﬀolds
1 + +
2 ++ +++
3 +++ ++
4 + ++
5 + ++
6 ++ ++
Range + to +++ + to +++
Type-II collagen immunoreactivity in the repair tissue of the defect was com-
pared to that of the normal articular cartilage adjacent to the defect, used as
a positive internal control.
Type-II collagen immunoreactivity was scored as follows:
−−, no immunoreactivity;
+, weaker immunoreactivity;
++, similar immunoreactivity;
+++, stronger immunoreactivity compared to the normal articular cartilage.
Table 2 Semiquantitative analysis of type-II collagen immunoreactivity in the repair
tissue after 3 weeks in vivo.
Immunohistochemical analysis of the repair tissue revealed more type-I collagen in the
repair tissue of defects receiving TGF-β1 scaﬀolds than in control defects (Figure 4G, H;
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Table 3).
Animal number Control Scaﬀolds TGF-ß1 Scaﬀolds
1 + +
2 + ++
3 + +
4 ++ +++
5 - +
6 ++ ++
Range - to ++ + to +++
Type-I collagen immunoreactivity in the repair tissue of the defect was com-
pared to that of the subchondral bone adjacent to the normal articular carti-
lage, used as a positive internal control.
Type-I collagen immunoreactivity was scored as follows:
−−, no immunoreactivity;
+, weaker immunoreactivity;
++, similar immunoreactivity;
+++, stronger immunoreactivity compared to the normal articular cartilage.
Table 3 Semiquantitative analysis of type-I collagen immunoreactivity in the repair tissue
after 3 weeks in vivo.
To study the eﬀects of TGF-ß1 on articular cartilage repair in vivo, the newly formed
repair tissue within the defect was evaluated using a previously published grading system
[18] that consists of eight individual parameters. When combined, values ranged from 31
(indicating an empty defect without repair tissue) to 0 points (indicating the complete
regeneration of normal articular cartilage). No complete articular cartilage regeneration
(0 points) was achieved at 3 weeks for defects treated with control or TGF-ß1 scaﬀolds.
Interestingly, nearly all individual categories of defects treated with TGF-ß1 scaﬀolds
received higher score values than defects treated with control scaﬀolds, indicative of a
lesser grade of cartilage repair than the control group. For example, the scores for the
ﬁlling of the defect and for the staining of the new tissue with safranin O, an indicator of
proteoglycans, were 2.6-fold worse in defects treated with TGF-ß1 scaﬀolds than in the
control group (Table 4). Although the average total score of TGF-β1-treated defects was
12 % higher (worse) than the average total score of control defects, statistical signiﬁcance
was not reached (Table 4).
The area that was safranin O-positive was 1, 137, 686±140, 494 μm2 in defects receiv-
ing control scaﬀolds and 798, 229 ± 687, 286 μm2, 42.5 % more than in defects receiving
TGF-β1 scaﬀolds (P > 0.005).
4 Discussion
The poor accessibility of the cartilage defect to agents that modulate chondrogenesis
is a major obstacle in the development of strategies to regenerate articular cartilage
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Category Control Scaﬀolds TGF-β Scaﬀolds P value
Mean (95 % CI) Mean (95 % CI)
Filling of the defect 0.55 (0.08 – 1.02) 1.41 (0.01 – 3.33) 0.34
Integration 1.56 (1.07 – 2.05) 1.87 (1.24 – 2.50) 0.34
Matrix staining 0.36 (0.11 – 0.61) 0.94 (0.00 – 2.28) 0.33
Cell morphology 2.83 (2.14 – 3.51) 2.91 (1.55 – 4.26) 0.85
Architecture of defect 3.09 (1.93 – 4.23) 3.08 (2.14 – 4.03) 0.99
Architecture of surface 2.05 (1.76 – 2.33) 2.21 (1.85 – 2.57) 0.47
New subchondral bone 2.86 (1.91 – 3.81) 3.18 (2.83 – 3.52) 0.34
Tidemark 3.98 (3.90 – 4.04) 3.79 (3.37 – 4.20) 0.31
Average total score 17.3 (14.6 – 19.8) 19.4 (13.5 – 25.3) 0.42
Each category and total score is based on the average of 2 independent evaluators. Means indicate
estimated scores in points for each category (lower scores indicate better healing). Comparisons were
made by repeated-measures ANOVA (knees within the same animal). CI = conﬁdence interval. No
statistically signiﬁcant diﬀerences were observed for any category (all P > 0.30).
Table 4 Eﬀects of TGF-ß1 on the histological grading of the repair tissue after three
weeks.
lesions. With a view to delivering a chondrogenic growth factor to an articular cartilage
defect, we developed a system that allowed for a controlled release of TGF-ß1 from
porous supportive structures. We tested the hypothesis that TGF-ß1 can be released
from these polymeric scaﬀolds over a prolonged period of time in vitro. We further
evaluated whether transplantation of such TGF-ß1 scaﬀolds into osteochondral defects
in the patellar groove of rabbits modulates articular cartilage repair in vivo. The data
indicate that human TGF-ß1 is eﬃciently released from poly(ether-ester) copolymeric
scaﬀolds over a minimum of 4 weeks in vitro. The data further suggest that delivery of
a cumulative dose of approximately 9 ng TGF-ß1 in 4 weeks via these scaﬀolds is not
suﬃcient to modulate articular cartilage repair in vivo.
The release of TGF-ß1 over a prolonged period of time is a prerequisite for the safe
and localized delivery of the protein to cartilage defects in vivo. The scaﬀolds employed
in the present study released a total cumulative amount of 7.5 ng TGF-ß1 after 8 days
and 9 ng TGF-ß1 after 28 days, conﬁrming the suitability of poly(ether-ester) copolymer
to release proteins [20, 21]. The mechanism of release from these hydrogel copolymers is
a combination of diﬀusion and matrix degradation. During the ﬁrst 8 days, the release
is likely to be mainly driven by diﬀusion mechanisms as the degradation of the coated
copolymer is minimal after 1 week [9]. The cumulative amount of TGF-ß1 released over
this period of time was relatively low when compared to the total amount entrapped in
the scaﬀolds. This reduced recovery may be linked to the denaturation of the protein
during the scaﬀold preparation or during release. It was previously demonstrated that
TGF-ß1 and lysozyme are not denaturated during the emulsion coating process and that
diﬀerent release rates can be obtained with the same scaﬀold.[8, 11] Therefore, the amount
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of TGF-ß1 released is possibly linked to the release proﬁle of the scaﬀold and the intrinsic
stability of the protein in the release medium between sampling. TGF-ß1 is an unstable
protein and its half-life in vivo is less than 30 min when in its active form [7]. In our
experiment, the absolute depletion of TGF-ß1 over 1 day in the release medium (RPMI
1640) was 93±2 %. Consequently, the cumulative amount of TGF-ß1 measured by ELISA
may reﬂect only a part of the TGF-ß1 that was eﬀectively released. Nevertheless, the
amounts of TGF-ß1 released in the present study are about 50-fold lower than applied by
Abe and colleagues in liposomes via intraarticular injection [22] and about 5- to 50-fold
lower than applied by Mierisch encapsulated in alginate spheres into articular cartilage
defects [23]. Additional studies need to test higher doses of TGF-ß1 using these scaﬀolds.
We designed the slow release system employed in the present study to maximize the
duration of defect’s exposure to the growth factor while avoiding undesirable intraarticular
side eﬀects. For example, when 500 ng TGF-ß1 encapsulated in liposomes were applied
by intraarticular injection, extensive ﬁbroblastic hyperplasia was seen [22]. Injection
of high doses of TGF-ß2 led to synovial hyperplasia and cartilage loss [24]. When an
adenoviral vector carrying a TGF-ß1 cDNA was injected intraarticularly to naive and
arthritic rabbit knee joints, a dose-dependent stimulation of glycosaminoglycan release
and nitric oxide production, and induction of ﬁbrogenesis and muscle edema were observed
[25]. In addition, chondrogenesis within the synovial lining was induced [25]. These results
suggest that TGF-ß1 may stimulate cartilage degradation and may serve to caution the
intraarticular application of high doses. The absence of elevated TGF-ß1 levels in the
synovial ﬂuid in the present study is probably due to the containment of the protein
within the new tissue. Such a lack of elevated intraarticular TGF-ß1 and of inﬂammatory
changes of the synovial membrane may be advantageous in a clinical setting, to avoid
undesirable eﬀects of the therapeutic factor.
After 3 weeks in vivo, the scaﬀolds remained underneath the original articular car-
tilage without any signs of adverse reactions. They allowed cartilage formation and the
formation of new subchondral trabecular bone. These features are important as the scaf-
fold integrated with the bony compartment. As the implanted scaﬀolds were devoid of
cells, the permeability towards ﬂuids is important to allow the progenitor cells present in
the bone marrow to reach the cartilage zone and to allow tissue ingrowth after implan-
tation in osteochondral defects. This was eﬀectively seen in vivo, as the scaﬀolds (either
control or TGF-ß1-scaﬀolds) showed tissue growth in the pores present in the bone area,
while cartilage was formed on top of the scaﬀolds. Scaﬀold fragments could be seen in
all animals indicating that the scaﬀolds dissolve very slowly thereby acting as a valuable
support for new bone and articular cartilage. These features of poly(ether-ester) copoly-
meric scaﬀolds may be desirable in tissue engineering and in clinical applications, as some
biomaterials have been shown to induce undesired eﬀects when applied intraarticularly
[26].
No diﬀerence in articular cartilage repair was seen in the present study following
transplantation of TGF-ß1 scaﬀolds compared to control scaﬀolds. This was somewhat
surprising, as previous studies reported improved cartilage repair following application
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of TGF-ß1 [22, 23]. In defects receiving TGF-ß1 scaﬀolds, trends towards an inhibition
of chondrogenesis were observed without reaching signiﬁcance. In particular, categories
indicative of proteoglycan synthesis, such as matrix staining and the area that stained
positive for safranin O, were inferior to defects treated with control scaﬀolds. When
TGF-ß1 encapsulated in liposomes was intraarticularly injected into the knee joints of
rabbits 1 week after creation of osteochondral cartilage defects, the early repair of these
defects was accelerated [22]. Similarly, when alginate spheres containing 50 or 500 ng
TGF-ß1 (per sphere) were applied to osteochondral defects in the trochlear grooves of
rabbits, better repair compared with controls was seen [23]. Others reported a trend
towards improvement of articular cartilage repair without statistical signiﬁcance when
polymer oligo[poly(ethylene glycol) fumarate] scaﬀolds containing TGF-ß1 were applied
to osteochondral defects in rabbits [27]. Earlier experiments using the scaﬀold applied in
the present study demonstrated that the TGF-ß released from the scaﬀold is bioactive
and is capable of modulating chondrogenesis in vitro [8]. One of the reasons for the lack
of a signiﬁcant eﬀect may be that the concentration of TGF-ß1 was 5- to 50-fold lower
than in other reports [22, 23]. It is also possible but unlikely that the eﬀect of TGF-
ß1 treatment would have become more evident at later time points. Using gene-based
treatments, signiﬁcant improvements in articular cartilage repair were already present
after 3 weeks in vivo [12–14] in an identical animal model.
Although mainly considered as a stimulator of articular cartilage repair, TGF-ß1 has
also been implicated in inhibiting chondrocyte maturation in vitro and in inducing alter-
ations of skeletal morphogenesis in vivo [28]. Galera and colleagues described diﬀerential
eﬀects of TGF-ß1 on major components of extracellular matrix, collagen, and proteogly-
cans, depending on the diﬀerentiation state of the cells [29]. Recently, it was reported
that TGF-ß1 can inhibit type-II collagen biosynthesis in primary articular chondrocytes at
transcriptional levels [30]. In a study by Hunziker and Rosenberg, application of 6 ng/ml
TGF-ß1 in a ﬁbrin matrix to partial-thickness (chondral) defects in Yucatan minipigs did
not lead to cartilage formation [31].
In summary, the results of the present study demonstrate that TGF-ß1 is released from
emulsion-coated scaﬀolds over a prolonged period of time in vitro. Scaﬀolds releasing a
cumulative dose of 9 ng TGF-ß1 that are applied to osteochondral defects in the knee
joints of rabbits do not signiﬁcantly modulate articular cartilage repair at 3 weeks in vivo.
In future, it will be important to address the relative importance of TGF-ß1 dose and
release kinetics of the scaﬀold employed. It will be essential to better characterize the
eﬀect of TGF-ß1 on chondrogenesis, perhaps in cartilage defects in a larger, clinically more
relevant animal model over an extended period of time. We are currently investigating
these possibilities. In addition, it will be critical to test other therapeutic factors involved
in enhancing articular cartilage repair. A better understanding of the role of TGF-ß1
within the context of a cartilage lesion will lead to improved strategies for articular
cartilage defects.
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